Exploring miR-21 Knock-Out Using CRISPR/Cas as a Treatment for Lung Cancer
Open Access
Abstract
Background: Lung cancer is a leading cause of cancer-related deaths worldwide. Its high incidence and poor prognosis demonstrate the need to investigate new therapies. The PI3K/AKT pathway is activated in carcinogenic processes such as invasion, proliferation, and drug resistance. MiR-21 is a microRNA overexpressed in numerous types of cancer and which activates PI3K/AKT pathway by down-regulating its main targets, PTEN and PDCD4. CRISPR is a revolutionary gene-editing technology that allows genes to be deleted. The aim of this study was to use CRISPR/Cas9 technology as an option to reduce carcinogenic and drug resistance processes by eliminating miR-21. Methods: CRISPR/Cas9 was used to knock out miR-21 (miR-21 KO) in A549 lung cancer cells and thus reverse the carcinogenic processes activated by miR-21 overexpression. Furthermore, the effect of miR-21 KO on drug resistance was studied, choosing the main chemotherapeutic agents used for the treatment of lung cancer: gemcitabine, carboplatin, paclitaxel, and oxaliplatin. Results: miR-21 KO A549 cells exhibited a reduction in proliferation, migration, and colony formation compared to A549 cells. In contrast, the expression of PTEN and PDCD4 increased in miR-21 KO A549 cells. Furthermore, miR-21 KO A549 cells showed a decrease in the IC50 of the drugs used for the treatment of lung cancer: gemcitabine, carboplatin, paclitaxel, and oxaliplatin. Conclusions: Based on these results, miR-21 knock-out using CRISPR/Cas could be a promising strategy for the treatment of lung cancer.Keywords
Funding Information
- the CTS-107 Group
This publication has 60 references indexed in Scilit:
- Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)Journal of Thoracic Oncology, 2021
- Mechanisms of resistance to chemotherapy in non-small cell lung cancerArchives of Pharmacal Research, 2021
- Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trialAnnals of Oncology, 2021
- Genome-edited adult stem cells: Next-generation advanced therapy medicinal productsStem Cells Translational Medicine, 2020
- Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancerCochrane Database of Systematic Reviews, 2020
- MiR‐21 improves invasion and migration of drug‐resistant lung adenocarcinoma cancer cell and transformation of EMT through targeting HBP1Cancer Medicine, 2018
- A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid LeukemiaCell Reports, 2016
- The Role of miR‐21 in CancerDrug Development Research, 2015
- Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancerBreast Cancer Research and Treatment, 2015
- Mechanisms involved in lung cancer development in COPDThe International Journal of Biochemistry & Cell Biology, 2011